Trial Profile
Treatment of Refractory Antibody-Mediated Rejection and Thrombotic Microangiopathy with Eculizumab
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 19 Aug 2015
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 19 Aug 2015 New trial record